0.445
-0.22 (-33.23%)
| Previous Close | 0.667 |
| Volume | 1,068,474 |
| Price / Sales | 0.060 |
| Price / Book | 0.130 |
| 52 Weeks Range |
| Profit Margin | -13.88% |
| Operating Margin (TTM) | -14.56% |
| Diluted EPS (TTM) | -5.76 |
| Quarterly Revenue Growth (YOY) | 18.00% |
| Total Debt/Equity (MRQ) | 4.12% |
| Current Ratio (MRQ) | 4.25 |
| Operating Cash Flow (TTM) | -11.06 M |
| Levered Free Cash Flow (TTM) | -10.60 M |
| Return on Assets (TTM) | -11.78% |
| Return on Equity (TTM) | -21.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Sunshine Biopharma Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 3.17% |
| % Held by Institutions | 1.74% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |